Company intelligence / Profile preview

江苏恩华赛德药业

Xuzhou, Jiangsu, China

Ownership: Private
Employees: ~4500
Development stage: Other

Overview

Jiangsu Nhwa Pharmaceutical (the parent of Enhua Sed) is a leading Chinese pharmaceutical company specializing in the central nervous system (CNS) field. It has successfully commercialized several anesthetic and psychotropic products, including Oliceridine (Olinvyk) licensed from Trevena, and maintains a robust pipeline of novel Class 1 drugs for schizophrenia and depression currently in mid-to-late stage clinical trials.

Therapeutic areas: PsychiatryNeurologyOther
Modalities: Small molecule
Industry: Biotech

Partnerships

TrevenaPaion AG

Beyond the preview

Go deeper on 江苏恩华赛德药业.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 江苏恩华赛德药业.

Explore the full profile